Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Inverness gets US antitrust green light for Cholestech buy:

This article was originally published in Clinica

Executive Summary

US antitrust authorities have approved Inverness Medical Innovations' proposed acquisition of heart disease diagnostics company Cholestech. Waltham, Massachusetts-based Inverness agreed to buy Cholestech in a stock-for-stock merger, where each Cholestech share is exchanged for 0.43642 Inverness shares (see Clinica No 1259, p 18). The transaction is slated to close in the third quarter of 2007.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT049309

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel